Cathepsin B-Responsive Liposomes for Controlled Anticancer Drug Delivery in Hep G2 Cells

Seulgi Lee; Su Jeong Song; Junseong Lee; Tai Hwan Ha; Joon Sig Choi

doi:10.3390/pharmaceutics12090876

journal article Open Access Sep 14, 2020

Cathepsin B-Responsive Liposomes for Controlled Anticancer Drug Delivery in Hep G2 Cells

Seulgi Lee Su Jeong Song Junseong Lee

Tai Hwan Ha

Joon Sig Choi

Pharmaceutics Vol. 12 No. 9 pp. 876 · MDPI AG

View at Publisher Save 10.3390/pharmaceutics12090876

Abstract

In recent decades, several types of anticancer drugs that inhibit cancer cell growth and cause cell death have been developed for chemotherapeutic application. However, these agents are usually associated with side effects resulting from nonspecific delivery, which may induce cytotoxicity in healthy cells. To reduce the nonspecific delivery issue, nanoparticles have been successfully used for the delivery of anticancer drugs to specific target sites. In this study, a functional polymeric lipid, PEG-GLFG-K(C16)2 (PEG-GLFG, polyethylene glycol-Gly-Leu-Phe-Gly-Lys(C16)2), was synthesized to enable controlled anticancer drug delivery using cathepsin B enzyme-responsive liposomes. The liposomes composed of PEG-GLFG/DOTAP (1,2-dioleoyl-3-trimethylammonium-propane (chloride salt))/DPPC (dipalmitoylphosphatidylcholine)/cholesterol were prepared and characterized at various ratios. The GLFG liposomes formed were stable liposomes and were degraded when acted upon by cathepsin B enzyme. Doxorubicin (Dox) loaded GLFG liposomes (GLFG/Dox) were observed to exert an effective anticancer effect on Hep G2 cells in vitro and inhibit cancer cell proliferation in a zebrafish model.

Topics

No keywords indexed for this article. Browse by subject →

References

28

[1]

Controlled drug delivery vehicles for cancer treatment and their performance

Sudipta Senapati, Arun Kumar Mahanta, Sunil Kumar et al.

Signal Transduction and Targeted Therapy 2018 10.1038/s41392-017-0004-3

[2]

Thorn "Doxorubicin pathways: Pharmacodynamics and adverse effects. Pharmacogenet" Genomics (2011)

[3]

Dasari "Cisplatin in cancer therapy: Molecular mechanisms of action" Eur. J. Pharmacol. (2014) 10.1016/j.ejphar.2014.07.025

[4]

Clarke "Clinical Pharmacokinetics of Docetaxel" Clin. Pharmacokinet. (1999) 10.2165/00003088-199936020-00002

[5]

Tran "Cancer nanomedicine: A review of recent success in drug delivery" Clin. Transl. Med. (2017) 10.1186/s40169-017-0175-0

[6]

Torchilin "Multifunctional, stimuli-sensitive nanoparticulate systems for drug delivery" Nat. Rev. Drug Discov. (2014) 10.1038/nrd4333

[7]

Wolfram "Clinical cancer nanomedicine" Nano Today (2019) 10.1016/j.nantod.2019.02.005

[8]

Sulheim "Smart cancer nanomedicine" Nat. Nanotechnol. (2019) 10.1038/s41565-019-0567-y

[9]

Daraee "Application of liposomes in medicine and drug delivery" Artif. Cells Nanomed. Biotechnol. (2014) 10.3109/21691401.2014.953633

[10]

Pattni "New Developments in Liposomal Drug Delivery" Chem. Rev. (2015) 10.1021/acs.chemrev.5b00046

[11]

Li "A photosensitive liposome with NIR light triggered doxorubicin release as a combined photodynamic-chemo therapy system" J. Control. Release (2018) 10.1016/j.jconrel.2018.02.001

[12]

Gu "NGR-modified pH-sensitive liposomes for controlled release and tumor target delivery of docetaxel" Colloids Surf. B (2017) 10.1016/j.colsurfb.2017.09.052

[13]

Kaplan "Phase II Study of Vincristine Sulfate Liposome Injection (Marqibo) and Rituximab for Patients With Relapsed and Refractory Diffuse Large B-Cell Lymphoma or Mantle Cell Lymphoma in Need of Palliative Therapy" Clin. Lymphoma Myeloma Leuk. (2014) 10.1016/j.clml.2013.09.009

[14]

Koudelka "Liposomal paclitaxel formulations" J. Control. Release (2012) 10.1016/j.jconrel.2012.09.006

[15]

Gondi "Cathepsin B as a cancer target" Expert Opin. Ther. Targets (2013) 10.1517/14728222.2013.740461

[16]

Song "Enzyme-responsive destabilization of stabilized plasmid-lipid nanoparticles as an efficient gene delivery" Eur. J. Pharm. Sci. (2016) 10.1016/j.ejps.2016.05.024

[17]

Lee, S., Son, S.J., Song, S.J., Ha, T.H., and Choi, J.S. (2017). Polyamidoamine (PAMAM) Dendrimers Modified with Cathepsin-B Cleavable Oligopeptides for Enhanced Gene Delivery. Polymers, 9. 10.3390/polym9060224

[18]

Ta "Thermosensitive liposomes for localized delivery and triggered release of chemotherapy" J. Control. Release (2013) 10.1016/j.jconrel.2013.03.036

[19]

Stewart "Challenges in carrier-mediated intracellular delivery: Moving beyond endosomal barriers" Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol. (2015) 10.1002/wnan.1377

[20]

Campbell "Phospholipid-cationic lipid interactions: Influences on membrane and vesicle properties" Biochim. Et Biophys. Acta (BBA)-Bioenerg. (2001) 10.1016/s0005-2736(01)00290-5

[21]

Terasawa "Activity levels of cathepsins B and L in tumor cells are a biomarker for efficacy of reovirus-mediated tumor cell killing" Cancer Gene Ther. (2015) 10.1038/cgt.2015.4

[22]

Nag "Surface Engineering of Liposomes for Stealth Behavior" Pharmaceutics (2013) 10.3390/pharmaceutics5040542

[23]

Garbuzenko "Effect of grafted PEG on liposome size and on compressibility and packing of lipid bilayer" Chem. Phys. Lipids (2005) 10.1016/j.chemphyslip.2005.02.003

[24]

Pramanik "Mitochondria Targeting Non-Isocyanate-Based Polyurethane Nanocapsules for Enzyme-Triggered Drug Release" Bioconjugate Chem. (2018) 10.1021/acs.bioconjchem.8b00460

[25]

Sheena "Functional evaluation of doxorubicin decorated polymeric liposomal curcumin: A surface tailored therapeutic platform for combination chemotherapy" New J. Chem. (2018) 10.1039/c8nj02406e

[26]

Dubbelboer, I.R., Pavlovic, N., Heindryckx, F., Sjögren, E., and Lennernas, H. (2019). Liver Cancer Cell Lines Treated with Doxorubicin under Normoxia and Hypoxia: Cell Viability and Oncologic Protein Profile. Cancers, 11. 10.3390/cancers11071024

[27]

Manov "High-dose acetaminophen inhibits the lethal effect of doxorubicin in Hep G2 cells: The role of P-glycoprotein and mitogen-activated protein kinase p44/42 pathway" J. Pharmacol. Exp. Ther. (2007) 10.1124/jpet.107.121772

[28]

Song "Amphiphilic Peptide Nanorods Based on Oligo-Phenylalanine as a Biocompatible Drug Carrier" Bioconjugate Chem. (2017) 10.1021/acs.bioconjchem.7b00247

Cited By

44

Enzyme-responsive strategy as a prospective cue to construct intelligent biomaterials for disease diagnosis and therapy

Meiyu Wang, Bin Gao · 2022

Biomaterials Science

Nano-based drug delivery systems: Conventional drug delivery routes, recent developments and future prospects

Afreen Sultana, Mina Zare · 2022

Medicine in Drug Discovery

Controlled Drug Delivery Systems: Current Status and Future Directions

Shivakalyani Adepu, Seeram Ramakrishna · 2021

Molecules

Metrics

44

Citations

28

References

Details

Published: Sep 14, 2020
Vol/Issue: 12(9)
Pages: 876
License: View

Authors

S

Seulgi Lee

Department of Biochemistry, Chungnam National University, Daejeon 34134, Korea

S

Su Jeong Song

Department of Biochemistry, Chungnam National University, Daejeon 34134, Korea

J

Junseong Lee

Department of Biochemistry, Chungnam National University, Daejeon 34134, Korea

T

Tai Hwan Ha

BioNanotechnology Research Center, Korea Research Institute of Bioscience and Biotechnology (KRIBB), Daejeon 34141, Korea; Department of Nanobiotechnology, KRIBB School of Biotechnology, Korea University of Science and Technology (UST), Daejeon 34113, Korea

J

Joon Sig Choi

Department of Biochemistry, Chungnam National University, Daejeon 34134, Korea

Funding

Bio & Medical Technology Development Program of the National Research Foundation (NRF) funded by the Korean government (MSIT) Award: NRF-2018M3A9B5024060 and NRF-2018M3A9B5024068

Cite This Article

Seulgi Lee, Su Jeong Song, Junseong Lee, et al. (2020). Cathepsin B-Responsive Liposomes for Controlled Anticancer Drug Delivery in Hep G2 Cells. Pharmaceutics, 12(9), 876. https://doi.org/10.3390/pharmaceutics12090876

Cathepsin B-Responsive Liposomes for Controlled Anticancer Drug Delivery in Hep G2 Cells

You May Also Like